심장 바이오마커 검사 시장 - 전략적 인사이트와 예측(2026-2035년)

The Cardiac Biomarker Testing Market is expected to grow at a CAGR of 10.5% from a market value of USD 11.0 billion in 2026 to USD 26.9 billion in 2035.

The cardiac biomarker testing market is undergoing significant transformation driven by the paradigm shift toward high-sensitivity diagnostics, the rising global burden of cardiovascular disease, and the increasing integration of rapid testing into emergency and decentralized care. The market's evolution is characterized by the growing recognition that objective biochemical evidence of myocardial injury, cardiac dysfunction, and ischemic events is essential for accurate diagnosis, risk stratification, and timely therapeutic intervention. The convergence of advanced immunoassay technologies, point-of-care platforms, and digital health integration is enabling faster, more sensitive, and increasingly accessible cardiac biomarker assessment. Healthcare systems are expanding emergency diagnostic capacity because shorter diagnostic turnaround directly influences treatment selection, hospital resource utilization, and patient prognosis. Clinical guidelines increasingly recommend high-sensitivity cardiac troponin testing, accelerating replacement of conventional biomarker assays in routine cardiovascular diagnosis. The market is witnessing significant investment in high-sensitivity assays, multiplex panels, and AI-enabled interpretation tools, positioning cardiac biomarker testing as a cornerstone of modern cardiovascular care.

Market Drivers

• The growing adoption of high-sensitivity cardiac troponin assays represents the primary driver for the cardiac biomarker testing market. High-sensitivity cardiac troponin represents the clinical standard for diagnosing myocardial injury. Hospitals are increasingly replacing conventional cardiac biomarker assays because earlier biomarker detection improves emergency department triage and reduces unnecessary hospital admissions. Clinical guideline alignment continues supporting procurement decisions, leading diagnostic manufacturers to expand high-sensitivity assay portfolios and automated laboratory compatibility, resulting in sustained growth in cardiac biomarker testing utilization. The rising global burden of cardiovascular diseases is further accelerating market growth through increased diagnostic demand. Cardiovascular disease remains one of the largest contributors to mortality and healthcare expenditure worldwide. Healthcare systems are increasing investments in early cardiovascular diagnosis because delayed detection significantly increases treatment complexity and long-term costs. Growing patient volumes therefore continue supporting routine adoption of cardiac biomarker testing across emergency medicine, cardiology, and intensive care settings. The expansion of point-of-care diagnostics is improving clinical decision-making in emergency and decentralized care. POCT provides faster clinical information during emergency care and decentralized healthcare delivery. Hospitals and ambulatory care facilities are expanding bedside diagnostic capabilities because shorter turnaround times improve therapeutic decision-making. Diagnostic manufacturers are developing compact analyzers with improved analytical sensitivity, strengthening demand for portable cardiac biomarker testing solutions. Increasing laboratory automation and digital integration is improving testing consistency and operational efficiency. Clinical laboratories rely on automated workflows to improve testing consistency and operational efficiency.

Market Restraints

• High-sensitivity cardiac biomarker assays require advanced analytical instrumentation and rigorous quality control, which limits adoption among smaller healthcare facilities with constrained laboratory budgets. The significant financial investment required for advanced platforms creates barriers for smaller facilities. Biomarker concentrations may be influenced by renal dysfunction, chronic cardiac conditions, or other comorbidities, increasing the need for clinical correlation and reducing reliance on a single diagnostic result. The biological variability of biomarkers creates challenges for consistent interpretation. Regulatory approval pathways continue requiring extensive analytical and clinical validation for new biomarker assays, extending product development timelines and delaying commercialization of emerging diagnostic technologies. The rigorous evidence requirements create significant time and cost burdens for developers. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Biomarker Type Insights

• The technology landscape is characterized by the growing importance of high-sensitivity immunoassays, automation, and digital integration. Cardiac troponin represents the clinical reference standard for detecting myocardial injury because of its superior specificity and sensitivity compared with traditional cardiac biomarkers. Hospitals are increasingly adopting high-sensitivity cardiac troponin assays as international clinical guidelines recommend accelerated diagnostic algorithms for suspected acute myocardial infarction. The transition requires laboratories to upgrade analytical platforms and validate standardized testing protocols across emergency departments. Diagnostic manufacturers are expanding high-sensitivity assay portfolios with improved analytical precision and broader automation compatibility. Immunoassays remain the dominant technology platform for cardiac biomarker detection. Clinical chemistry continues supporting complementary biomarker assessment. The segment analysis reveals that acute myocardial infarction remains the primary clinical application because treatment outcomes depend heavily on rapid diagnosis. Emergency departments are increasingly implementing serial high-sensitivity troponin protocols that support accelerated rule-in and rule-out strategies. POCT enables clinicians to obtain cardiac biomarker results close to the patient, reducing diagnostic turnaround time during emergency evaluation. Hospitals represent the leading end-user segment, with clinical laboratories and emergency care settings expanding testing capabilities. The integration of AI is becoming increasingly important because digital healthcare platforms increasingly combine laboratory data with clinical decision-support systems. Healthcare organizations are implementing AI algorithms because integrated interpretation improves patient risk stratification and supports standardized treatment pathways.

Competitive and Strategic Outlook

• The competitive landscape features established diagnostics and life science companies alongside specialized point-of-care, immunoassay, and digital health providers. Abbott maintains a leading position through its comprehensive immunoassay portfolio, global installed base of automated analyzers, and strong clinical evidence supporting high-sensitivity cardiac troponin testing, integrating cardiac biomarker assays across the ARCHITECT, Alinity, and related laboratory platforms. Roche remains strategically differentiated through its extensive immunodiagnostics expertise and strong integration of cardiac biomarkers within the Elecsys testing portfolio, focusing on delivering highly standardized assays that support accurate diagnosis of myocardial injury and cardiovascular risk assessment. Siemens Healthineers distinguishes itself through integrated laboratory automation and advanced immunoassay technologies that support high-throughput cardiovascular diagnostics, combining its Atellica Solution and ADVIA Centaur platforms with high-sensitivity cardiac biomarker assays. bioMerieux differentiates itself through its strong expertise in in vitro diagnostics, microbiology, immunoassays, and integrated laboratory solutions that support timely clinical decision-making. QuidelOrtho maintains a competitive position through its diversified portfolio of laboratory-based and point-of-care diagnostic solutions, enabling healthcare providers to deliver rapid clinical decisions across emergency and decentralized care settings. Danaher maintains a strong strategic position through its life sciences and diagnostics portfolio, supported by subsidiaries that provide advanced laboratory instruments, immunoassay technologies, and automation solutions. Companies are pursuing product portfolio expansion through innovation in high-sensitivity assays, multiplex panels, and AI-enabled interpretation tools. Recent key developments include UCLA researchers developing an AI-powered portable diagnostic platform for rapid, multiplexed detection of key cardiac biomarkers, measuring cTnI, CK-MB, and NT-proBNP in about 23 minutes using dual-mode optical sensing plus neural network analysis. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

• The cardiac biomarker testing market is positioned for sustained growth driven by the convergence of disease burden, technological innovation, and clinical guideline evolution. The transition from conventional assays toward high-sensitivity, multiplex, and decentralized testing platforms represents a fundamental shift in cardiovascular diagnostics. While challenges related to high costs, biological variability, and regulatory complexity persist, strategic investments in technology, automation, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with cardiac biomarker testing evolving into a cornerstone of modern cardiovascular care, supporting rapid diagnosis, risk stratification, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Cardiac Biomarker Testing Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Disease Burden & Clinical Importance of Cardiac Biomarkers
• 3.8 Epidemiology of Cardiovascular Diseases
  • 3.8.1 Disease Prevalence
  • 3.8.2 Diagnosed Patient Population
• 3.9 Testing Volume Analysis
• 3.10 Clinical Testing Workflow
• 3.11 Biomarker Utilization in Acute and Chronic Cardiac Conditions
• 3.12 Clinical Practice Guidelines and Testing Recommendations

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Biomarker Technologies
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 Multiplex and High-Sensitivity Assay Development
• 6.6 AI Integration in Cardiac Biomarker Interpretation
• 6.7 Digital Health Integration and Connected Diagnostics

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Cardiac Biomarker Testing Market Landscape Analysis

• 8.1 Analysis by Biomarker Type
• 8.2 Analysis by Technology Platform
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by Testing Methodology
• 8.6 Analysis by Testing Setting

9. Global Cardiac Biomarker Testing Market Segment Analysis (2021-2035)

• 9.1 By Biomarker Type
  • 9.1.1 Cardiac Troponin (cTnI & cTnT)
  • 9.1.2 Creatine Kinase-MB (CK-MB)
  • 9.1.3 Myoglobin
  • 9.1.4 Ischemia-Modified Albumin (IMA)
  • 9.1.5 Other Cardiac Biomarkers
• 9.2 By Technology Platform
  • 9.2.1 Immunoassays
  • 9.2.2 Clinical Chemistry
  • 9.2.3 Molecular Diagnostics
  • 9.2.4. Other Technologies
• 9.3 By Testing Method
  • 9.3.1 Laboratory-Based Testing
  • 9.3.2 Point-of-Care Testing (POCT)
• 9.4 By Sample Type
  • 9.4.1 Whole Blood
  • 9.4.2 Serum
  • 9.4.3 Plasma
• 9.5 By Clinical Application
  • 9.5.1 Acute Myocardial Infarction
  • 9.5.2 Acute Coronary Syndrome
  • 9.5.3 Heart Failure
  • 9.5.4 Risk Stratification
  • 9.5.5 Other Cardiovascular Conditions
• 9.6 By End User
  • 9.6.1 Hospitals
  • 9.6.2 Clinical Laboratories
  • 9.6.3 Emergency Care Settings
  • 9.6.4 Others

10. Global Cardiac Biomarker Testing Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Cardiac Biomarker Testing Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 Abbott Laboratories
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 F. Hoffmann-La Roche AG
• 13.3 Siemens Healthineers
• 13.4 Chembio Diagnostics
• 13.5 bioMerieux
• 13.6 QuidelOrtho Corporation
• 13.7 Abcam plc
• 13.8 LumiraDx Limited
• 13.9 Danaher Corporation
• 13.10 Thermo Fisher Scientific

14. Global Cardiac Biomarker Testing Market Commercial Forecast Analysis

• 14.1 Cardiac Troponin Testing
• 14.2 BNP Testing
• 14.3 NT-proBNP Testing
• 14.4 CK-MB Testing
• 14.5 Myoglobin Testing
• 14.6 Multiplex Cardiac Biomarker Panels
• 14.7 Point-of-Care Cardiac Biomarker Testing
• 14.8 High-Sensitivity Cardiac Biomarker Testing

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends